The Food and Drug Administration (FDA) ISTAND Pilot Program Accepts Submission of First AI-Based Technology for Neuroscience
Summary
The FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program is designed to encourage the use of innovative methods, materials or measures that have the potential to facilitate drug development in a specified area of need. The agency’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) accepted the first AI-based, digital health technology project in neuroscience. This tool utilizes multiple behavioral and physiological indices of depression and anxiety in a machine learning model to derive severity measurements.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.